Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: The Dutch experience

D Mul*, W Oostdijk, BJ Otten, C Rouwe, M Jansen, HA Delemarre-van de Waal, JJJ Waelkens, SLS Drop

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

51 Citations (Scopus)

Abstract

Final height (FH) data of 96 children (87 girls) treated with GnRH agonist for central precocious puberty were studied. In girls mean FH exceeded initial height prediction by 7.4 (5.7) cm (p <0.001); FH was significantly lower than target height, but still in the genetic target range. When treatment started <6 years of age, height gain was significantly higher than when started > 8 years of age. Bone age (BA) and chronological age (CA) at start of treatment, as well as BA advance at cessation of treatment, were the most important variables influencing height gain in multiple regression analysis. BA advance at start of treatment was most important in simple correlation. In girls, GnRHa treatment seems to restore FH into the target range. A younger age and advanced bone age at start of treatment are associated with more height gain from GnRHa treatment.

Original languageEnglish
Pages (from-to)765-772
Number of pages8
JournalJournal of pediatric endocrinology & metabolism
Volume13
Publication statusPublished - Jul-2000
EventEuropean Conference on Diagnosis and Treatment of Central Precocious Puberty: State of the Art 1999 - , Italy
Duration: 3-Dec-19994-Dec-1999

Keywords

  • final height
  • GnRHa treatment
  • discontinuation
  • central precocious puberty
  • predicted adult height
  • LONG-TERM TREATMENT
  • ANALOG THERAPY
  • GNRH AGONIST
  • ADULT HEIGHT
  • SLOW-RELEASE
  • GIRLS
  • GROWTH
  • CHILDREN
  • AGE

Cite this